Get started
Work

Abstract CT227: KEYNOTE-495/KeyImPaCT: Phase II biomarker-directed precision oncology study of pembrolizumab-based combination therapy for non-small cell lung cancer

Year: 2019
Type: conference-abstract
DOI: 10.1158/1538-7445.am2019-ct227
Authors: Martin Gutierrez, Matthew D. Hellmann, Matthew Gubens, Charu Aggarwal, Daniel Shao Weng Tan, Enriqueta Felip, Joanne Wing Yan Chiu, Jong-Seok Lee, James Chih-Hsin Yang, Edward Garon, Andrea D. Basso, Hua Ma, Lawrence Fong, Alex Snyder, Jianda Yuan, Roy S. Herbst
Institutions: Hackensack University Medical Center, Memorial Sloan Kettering Cancer Center, University of California, San Francisco, University of California San Francisco Medical Center, University of Pennsylvania, National University of Singapore, SingHealth Duke-NUS Academic Medical Centre, Duke-NUS Medical School, Vall d'Hebron Hospital Universitari, University of Hong Kong, Seoul National University Bundang Hospital, National Taiwan University, University of California, Los Angeles, Merck & Co., Inc., Rahway, NJ, USA (United States), Yale University
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: closed
OpenAlex ID: W2956090854
Cites:
Cited by:
Related to: 10